Summary
Clinical trials have shown that antiplatelet agents are effective in the prevention of thrombosis in arterial diseases and increase bleeding time. To compare the effects of three such drugs [acetylsalicylic acid (ASA) at two dose levels, ticlopidine and indobufen] on bleeding time, we performed a randomized cross-over study on 12 normal subjects. All received the four treatments (ASA 300 mg daily and 500 mg twice daily, ticlopidine 250 mg twice daily and indobufen 200 mg twice daily, each for 6 days plus one dose on day 7) in a sequential manner with a washout period of 15 days between the treatments. Bleeding time was measured using a Surgicut device (Ortho, Milan, Italy) before treatment, 2 and 24 h after the first administration, and before and 2, 24, 48 and 72 h after the last administration. ASA (at both doses) and indobufen quickly induced a significant prolongation of bleeding time, but the effect of indobufen soon wore off after the treatment was stopped, unlike that of ASA. In contrast, ticlopidine treatment prolonged bleeding time only after the first 24 h, and after 7 days the mean value was significantly higher than with ASA (both doses) and indobufen. This significant difference in bleeding time between ticlopidine and the other drugs was still present 48 h after the end of treatment.
Article PDF
Avoid common mistakes on your manuscript.
References
Antiplatelet Trialists' Collaboration, Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ p 296, 1988
Bailey BJR, Tables of the Bonferroni “t” statistics, J Am Stat Assoc 72:469, 1977
Cochran WG, Cox GM, Experimental design. Wiley, New York, p 17, 1950
Dalla Volta S, Antiplatelet treatment in the prevention of reocclusion after PTCA: an Italian multicenter study. Blood 74 [Suppl 1]:1769, 1989
Defreyn G, Bernat A, Delebrassee Maffraud P, Pharmacology of ticlopidine: a review. Semin Thromb Hemost 15:159, 1989
Ellis DJ, Roerl Burno JJ, Cranston BJ, McSpadden MM, The effects of ticlopidine hydrochloride on bleeding time and platelet function in man. Thromb Haemost 46:1973, 1981
Gent M, Easton JD, Hachinski VC, Sicurella J, Blakel JA, Ellis DJ, Harbison JW, Roberts RS, Turpie AGG, and the CATS group, The Canadian American ticlopidine study (CATS) on thromboembolic stroke. Lancet p 1217, 1989
Hass WK, Easton JD, Adams HP, Pryse PW, Molony BA, Anderson S, Kamm B, A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 321:501, 1989
Kallmann R, Nieuwenhuis HK, De Groot PG, Van Gijn J, Sixma JJ, Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PG F1a excretion in healthy subjects. Thromb Res 45:355, 1987
Mannucci L, Maderna P, Colli S, Lavezzari M, Sirtori CR, Tremoli E, Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk. Thromb Res 48:417, 1987
Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA, Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 17:317, 1980
Pogliani E, Corvi G, Mandelli V, Fuccella LM, Preliminary human pharmacology studies on the inhibition of platelet aggregation by Indobufen (K 3920). Haematologica (Pavia) 66:1, 1981
Rovelli F, Indobufen versus aspirin+dipyridamole in preventing early aortocoronary graft occlusion: a double blind randomized multicenter study. Blood 74 [Suppl 1]:1769, 1981
Violi F, Scrutini D, Ciminiello C et al., S.T.A.I. (Study of Ticlopidine in Unstable Angina) (abstract). J Am Coll Cardiol 13 [Suppl A]:238A, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pogliani, E.M., Fowst, C., Bregani, R. et al. Bleeding time and antiplatelet agents in normal volunteers. Int J Clin Lab Res 22, 58–61 (1992). https://doi.org/10.1007/BF02591396
Issue Date:
DOI: https://doi.org/10.1007/BF02591396